Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials.

Liver Int · 2020 · PMC7187170 · PMID 31568620

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

In the mITT population, which excludes patients with non‐virological failure, there was a marginally significant difference in overall SVR12 rates between patients who were adherent and those who were non‐adherent to G/P therapy (Figure 1 B).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.